Insulin-like Growth Factor-I Activates Gene Transcription Programs Strongly Associated with Poor Breast Cancer Prognosis

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2008 Sep 2

PMID 18757322

Citations 143

Authors

Chad J Creighton

Angelo Casa

ZaWaunyka Lazard

Shixia Huang

Anna Tsimelzon

Susan G Hilsenbeck

Charles Kent Osborne

Adrian V Lee

Affiliations

Soon will be listed here.

Abstract

Purpose: Substantial evidence implicates insulin-like growth factor-I (IGF-I) signaling in the development and progression of breast cancer. To more clearly elucidate the role of IGF in human breast cancer, we identified and then examined gene expression patterns of IGF-I-treated breast cancer cells.

Methods: MCF-7 cells were stimulated with IGF-I for 3 or 24 hours and were profiled for greater than 22,000 RNA transcripts. We defined an IGF-I signature pattern of more than 800 genes that were up- or downregulated at both time points. The gene signature was examined in clinical breast tumors and in experimental models that represented other oncogenic pathways. The signature was correlated with clinical and pathologic variables and with patient outcome.

Results: IGF-I caused temporal changes in gene expression that were strongly associated with cell proliferation, metabolism, and DNA repair. Genes with early and sustained regulation by IGF-I were highly enriched for transcriptional targets of the estrogen receptor (ER), Ras/extracellular signal-related kinase 1/2, and phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathways. In three large, independent data sets of profiled human breast tumors, the IGF-I signature was manifested in the majority of ER-negative breast tumors and in a subset (approximately 25%) of ER-positive breast tumors. Patients who had tumors that manifested the IGF-I signature (including patients who did not receive adjuvant therapy) had a shorter time to a poor outcome event. The IGF gene signature was highly correlated with numerous poor prognostic factors and was one of the strongest indicators of disease outcome.

Conclusion: Transcriptional targets of IGF-I represent pathways of increased aggressiveness and possibly hormone independence in clinical breast cancers.

Citing Articles

E-Cadherin-Mediated Cell-Cell Adhesion and Invasive Lobular Breast Cancer.

Bullock E, Brunton V Adv Exp Med Biol. 2025; 1464():259-275.

PMID: 39821030 DOI: 10.1007/978-3-031-70875-6_14.

Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.

Rediti M, Venet D, Joaquin Garcia A, Maetens M, Vincent D, Majjaj S Nat Commun. 2024; 15(1):10402.

PMID: 39613746 PMC: 11607438. DOI: 10.1038/s41467-024-54621-3.

Targeting IGF-IR improves neoadjuvant chemotherapy efficacy in breast cancers with low IGFBP7 expression.

Godina C, Pollak M, Jernstrom H NPJ Precis Oncol. 2024; 8(1):212.

PMID: 39362991 PMC: 11450189. DOI: 10.1038/s41698-024-00712-9.

Associations in cell type-specific hydroxymethylation and transcriptional alterations of pediatric central nervous system tumors.

Lee M, Azizgolshani N, Zhang Z, Perreard L, Kolling F, Nguyen L Nat Commun. 2024; 15(1):3635.

PMID: 38688903 PMC: 11061294. DOI: 10.1038/s41467-024-47943-9.

Regulation of IGF1R by MicroRNA-15b Contributes to the Anticancer Effects of Calorie Restriction in a Murine C3-TAg Model of Triple-Negative Breast Cancer.

Bustamante-Marin X, Devlin K, McDonell S, Dave O, Merlino J, Grindstaff E Cancers (Basel). 2023; 15(17).

PMID: 37686596 PMC: 10486801. DOI: 10.3390/cancers15174320.

References

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron J, Nobel A . Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100(14):8418-23. PMC: 166244. DOI: 10.1073/pnas.0932692100. View

Pollak M . Insulin-like growth factor physiology and cancer risk. Eur J Cancer. 2000; 36(10):1224-8. DOI: 10.1016/s0959-8049(00)00102-7. View

Pacher M, Seewald M, Mikula M, Oehler S, Mogg M, Vinatzer U . Impact of constitutive IGF1/IGF2 stimulation on the transcriptional program of human breast cancer cells. Carcinogenesis. 2006; 28(1):49-59. DOI: 10.1093/carcin/bgl091. View

Saldanha A . Java Treeview--extensible visualization of microarray data. Bioinformatics. 2004; 20(17):3246-8. DOI: 10.1093/bioinformatics/bth349. View

Allred D, Brown P, Medina D . The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res. 2004; 6(6):240-5. PMC: 1064085. DOI: 10.1186/bcr938. View

Wang Y, Klijn J, Zhang Y, Sieuwerts A, Look M, Yang F . Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005; 365(9460):671-9. DOI: 10.1016/S0140-6736(05)17947-1. View

Creighton C, Cordero K, Larios J, Miller R, Johnson M, Chinnaiyan A . Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors. Genome Biol. 2006; 7(4):R28. PMC: 1557996. DOI: 10.1186/gb-2006-7-4-r28. View

Whitfield M, Sherlock G, Saldanha A, Murray J, Ball C, Alexander K . Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell. 2002; 13(6):1977-2000. PMC: 117619. DOI: 10.1091/mbc.02-02-0030. View

Eisen M, Spellman P, Brown P, Botstein D . Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998; 95(25):14863-8. PMC: 24541. DOI: 10.1073/pnas.95.25.14863. View

10.

Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills G . Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity.... Mol Endocrinol. 2003; 17(4):575-88. DOI: 10.1210/me.2002-0318. View

11.

Ma X, Wang Z, Ryan P, Isakoff S, Barmettler A, Fuller A . A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 2004; 5(6):607-16. DOI: 10.1016/j.ccr.2004.05.015. View

12.

van de Vijver M, He Y, Vant Veer L, Dai H, Hart A, Voskuil D . A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347(25):1999-2009. DOI: 10.1056/NEJMoa021967. View

13.

Thorne C, Lee A . Cross talk between estrogen receptor and IGF signaling in normal mammary gland development and breast cancer. Breast Dis. 2005; 17:105-14. DOI: 10.3233/bd-2003-17110. View

14.

Knowlden J, Hutcheson I, Barrow D, Gee J, Nicholson R . Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology. 2005; 146(11):4609-18. DOI: 10.1210/en.2005-0247. View

15.

Fan C, Oh D, Wessels L, Weigelt B, Nuyten D, Nobel A . Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006; 355(6):560-9. DOI: 10.1056/NEJMoa052933. View

16.

Miller L, Smeds J, George J, Vega V, Vergara L, Ploner A . An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A. 2005; 102(38):13550-5. PMC: 1197273. DOI: 10.1073/pnas.0506230102. View

17.

Bild A, Yao G, Chang J, Wang Q, Potti A, Chasse D . Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2005; 439(7074):353-7. DOI: 10.1038/nature04296. View

18.

J van t Veer L, Dai H, van de Vijver M, He Y, Hart A, Mao M . Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415(6871):530-6. DOI: 10.1038/415530a. View

19.

Yee D, Lee A . Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mammary Gland Biol Neoplasia. 2000; 5(1):107-15. DOI: 10.1023/a:1009575518338. View

20.

Sachdev D, Yee D . Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther. 2007; 6(1):1-12. DOI: 10.1158/1535-7163.MCT-06-0080. View